Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Nov;66(5):810–814. doi: 10.1038/bjc.1992.365

Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas.

K Koretz 1, S Brüderlein 1, C Henne 1, P Möller 1
PMCID: PMC1977964  PMID: 1384641

Abstract

Decay-accelerating-factor (DAF, CD55), a phosphatidyl-inositol anchored glycoprotein, is a member of the cell membrane bound complement regulatory proteins that inhibit autologous complement cascade activation. DAF was found expressed on cells that are in close contact with serum complement proteins, but also on cells outside the vascular space and on tumour cells. Using CD55(BRIC110) and CD55(143-30) we show here that DAF(CD55) is only sporadically expressed on the luminal surface of normal colonic epithelium. However, 5/20 adenomas expressed DAF(CD55) on the cell surface of all tumour cells, 5/20 adenomas were completely negative, 10/20 adenomas expressed DAF(CD55) in various amounts. DAF(CD55) was expressed in various intensities on almost all tumour cells of the colon carcinoma cell line HT29. In 5/88 colorectal carcinomas DAF(CD55) was localised on the apical cell surface of all tumour cells, 31/88 were completely negative, 52/88 expressed DAF(CD55) in parts of their neoplastic populations. There was no correlation between the tumour grading, staging and location and the mode of DAF(CD55) expression, but DAF(CD55) was found more often in mucinous carcinomas (P = 0.007). Although the mode of DAF(CD55) expression is not correlated with tumour prognostic parameters, the upregulation of DAF(CD55) in a subset of adenomas and carcinomas needs further investigation concerning protection of tumour cells against complement cytotoxicity.

Full text

PDF
810

Images in this article

811Figure 1
on p.811
812Figure 2
on p.812
813Figure 3
on p.813
813Figure 4
on p.813

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asch A. S., Kinoshita T., Jaffe E. A., Nussenzweig V. Decay-accelerating factor is present on cultured human umbilical vein endothelial cells. J Exp Med. 1986 Jan 1;163(1):221–226. doi: 10.1084/jem.163.1.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berger M., Medof M. E. Increased expression of complement decay-accelerating factor during activation of human neutrophils. J Clin Invest. 1987 Jan;79(1):214–220. doi: 10.1172/JCI112786. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cheung N. K., Walter E. I., Smith-Mensah W. H., Ratnoff W. D., Tykocinski M. L., Medof M. E. Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest. 1988 Apr;81(4):1122–1128. doi: 10.1172/JCI113426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. DUKES C. E., BUSSEY H. J. The spread of rectal cancer and its effect on prognosis. Br J Cancer. 1958 Sep;12(3):309–320. doi: 10.1038/bjc.1958.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Davis L. S., Patel S. S., Atkinson J. P., Lipsky P. E. Decay-accelerating factor functions as a signal transducing molecule for human T cells. J Immunol. 1988 Oct 1;141(7):2246–2252. [PubMed] [Google Scholar]
  6. Davitz M. A. Decay-accelerating factor (DAF): a review of its function and structure. Acta Med Scand Suppl. 1987;715:111–121. doi: 10.1111/j.0954-6820.1987.tb09911.x. [DOI] [PubMed] [Google Scholar]
  7. Fujita T., Inoue T., Ogawa K., Iida K., Tamura N. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. J Exp Med. 1987 Nov 1;166(5):1221–1228. doi: 10.1084/jem.166.5.1221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kinoshita T. Biology of complement: the overture. Immunol Today. 1991 Sep;12(9):291–295. doi: 10.1016/0167-5699(91)90001-A. [DOI] [PubMed] [Google Scholar]
  9. Kinoshita T., Medof M. E., Nussenzweig V. Endogenous association of decay-accelerating factor (DAF) with C4b and C3b on cell membranes. J Immunol. 1986 May 1;136(9):3390–3395. [PubMed] [Google Scholar]
  10. Kinoshita T., Medof M. E., Silber R., Nussenzweig V. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med. 1985 Jul 1;162(1):75–92. doi: 10.1084/jem.162.1.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lisanti M. P., Caras I. W., Davitz M. A., Rodriguez-Boulan E. A glycophospholipid membrane anchor acts as an apical targeting signal in polarized epithelial cells. J Cell Biol. 1989 Nov;109(5):2145–2156. doi: 10.1083/jcb.109.5.2145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Low M. G. Biochemistry of the glycosyl-phosphatidylinositol membrane protein anchors. Biochem J. 1987 May 15;244(1):1–13. doi: 10.1042/bj2440001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lublin D. M., Atkinson J. P. Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol. 1989;7:35–58. doi: 10.1146/annurev.iy.07.040189.000343. [DOI] [PubMed] [Google Scholar]
  14. Lublin D. M., Lemons R. S., Le Beau M. M., Holers V. M., Tykocinski M. L., Medof M. E., Atkinson J. P. The gene encoding decay-accelerating factor (DAF) is located in the complement-regulatory locus on the long arm of chromosome 1. J Exp Med. 1987 Jun 1;165(6):1731–1736. doi: 10.1084/jem.165.6.1731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Medof M. E., Kinoshita T., Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med. 1984 Nov 1;160(5):1558–1578. doi: 10.1084/jem.160.5.1558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Medof M. E., Walter E. I., Rutgers J. L., Knowles D. M., Nussenzweig V. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med. 1987 Mar 1;165(3):848–864. doi: 10.1084/jem.165.3.848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Mold C., Walter E. I., Medof M. E. The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor. J Immunol. 1990 Dec 1;145(11):3836–3841. [PubMed] [Google Scholar]
  18. Momburg F., Moldenhauer G., Hämmerling G. J., Möller P. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res. 1987 Jun 1;47(11):2883–2891. [PubMed] [Google Scholar]
  19. Nicholson-Weller A., Burge J., Fearon D. T., Weller P. F., Austen K. F. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol. 1982 Jul;129(1):184–189. [PubMed] [Google Scholar]
  20. Nicholson-Weller A., March J. P., Rosen C. E., Spicer D. B., Austen K. F. Surface membrane expression by human blood leukocytes and platelets of decay-accelerating factor, a regulatory protein of the complement system. Blood. 1985 May;65(5):1237–1244. [PubMed] [Google Scholar]
  21. Quigg R. J., Nicholson-Weller A., Cybulsky A. V., Badalamenti J., Salant D. J. Decay accelerating factor regulates complement activation on glomerular epithelial cells. J Immunol. 1989 Feb 1;142(3):877–882. [PubMed] [Google Scholar]
  22. Sayama K., Shiraishi S., Shirakata Y., Kobayashi Y., Miki Y. Characterization of decay-accelerating factor (DAF) in human skin. J Invest Dermatol. 1991 Jan;96(1):61–64. doi: 10.1111/1523-1747.ep12514737. [DOI] [PubMed] [Google Scholar]
  23. Spring F. A., Judson P. A., Daniels G. L., Parsons S. F., Mallinson G., Anstee D. J. A human cell-surface glycoprotein that carries Cromer-related blood group antigens on erythrocytes and is also expressed on leucocytes and platelets. Immunology. 1987 Oct;62(2):307–313. [PMC free article] [PubMed] [Google Scholar]
  24. Terachi T., Stanescu G., Pontes J. E., Medof M. E., Caulfield M. J. Coexistence of autologous antibodies and decay-accelerating factor, an inhibitor of complement, on human renal tumor cells. Cancer Res. 1991 May 15;51(10):2521–2523. [PubMed] [Google Scholar]
  25. Werth V. P., Ivanov I. E., Nussenzweig V. Decay-accelerating factor in human skin is associated with elastic fibers. J Invest Dermatol. 1988 Nov;91(5):511–516. doi: 10.1111/1523-1747.ep12476743. [DOI] [PubMed] [Google Scholar]
  26. Zimmermann A., Gerber H., Nussenzweig V., Isliker H. Decay-accelerating factor in the cardiomyocytes of normal individuals and patients with myocardial infarction. Virchows Arch A Pathol Anat Histopathol. 1990;417(4):299–304. doi: 10.1007/BF01605780. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES